The Human Variable 

Infection-associated chronic conditions (IACCs), including Long COVID, ME/CFS, post-treatment Lyme disease syndrome (PTLDS), and related post-infectious syndromes, present a persistent challenge to conventional medical workflows. These conditions are multi-system, fluctuating, and temporally delayed, with symptom expression shaped by environmental exposures, autonomic regulation, immune reactivity, hormonal state, and cumulative demand.

CDF-POTS is a new AI powered diagnostic fingerprint that captures the hidden patterns of POTS across cognitive, cardiac, vascular, and orthostatic domains. An estimated 16.5M Americans are living with POTS, most without a formal diagnosis. This model removes diagnostic waste by 86 percent, cuts ER visits by 70 percent, and restores workforce participation while saving the United States up to 400B dollars annually.

By October 2025, CYNAERA’s federal-scale models identified between $1.05 trillion and $3.45 trillion in potential annual savings for the United States through modular frameworks that stabilize health, accelerate remission, and optimize budgetary flow across SSA, CMS, VA, and FEMA

The COVID-19 pandemic has added another layer of immune instability through persistent inflammation, viral reactivations, and population-wide biologic stress . CRATE™ converts these complex dynamics into actionable modeling signals to inform future prevention strategy

The CYNAERA Primary Chronic Trigger (PCT) framework embeds PEM as a probability-weighted conversion event inside a prevalence model that accounts for viral exposure, environmental load, climate volatility, and recovery suppression. Modeled remission rises from historical 12–18 percent toward 35–50 percent under PEM-aware, terrain-timed designs, with early-intervention subsets reaching 42–60 percent in best-case conditions.

Bioadaptive Systems Therapeutics™ (BST) is a new discipline of medicine that engineers remission by recalibrating fragile biological systems across immune, autonomic, mitochondrial, connective, hormonal, and environmental domains. Unlike traditional medicine, which classifies disease onset and treats within rigid silos, BST is phase-aware, terrain-first, and subtype-specific.